Ratings Metagenomi, Inc.

Equities

MGX

US59102M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
6.08 ^USD	-8.30%		-4.70%	0.00%

May. 14	Metagenomi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
METAGENOMI, INC.	0.00%	228M	-	-
MODERNA, INC.	+51.85%	57.87B		B-
LONZA GROUP AG	+41.42%	40.25B		A
IQVIA HOLDINGS INC.	-5.25%	39.94B		B
CELLTRION, INC.	-5.16%	28.54B		C
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B		B-
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B		B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B		C+
BIO-TECHNE CORPORATION	+0.61%	12.23B		B+
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes